Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
BriefSTAT News
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
BriefSTAT News
Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.